Abstract
The study of tachykinin NK1 (substance P) receptor antagonists has emerged as a field of great promise due to accumulating evidence that NK1 antagonists offer possible new treatment options in therapeutic areas ranging from pain, emesis, and pulmonary disorders to depression and anxiety. It is hoped that the unique mechanism of action of these agents, which involves modulation of effects mediated by the interaction of the neuropeptide substance P with its Gprotein coupled receptor, will provide improvements over existing therapies. For this reason many pharmaceutical companies are engaged in intense research programs with the goal of bringing safe and effective new drugs to the market. To date a wealth of diverse NK1 antagonists have been discovered, several of which have been evaluated in clinical trials. Despite rich structural diversity in this area of medicinal chemistry a number of structural features are commonly shared amongst otherwise unrelated antagonists. This theme and others are covered with the aim of conveying recent successful approaches to the discovery of potent and selective nonpeptide NK1 antagonists. This review focuses mainly on reports appearing in the year 2001 and the first half of 2002.
Keywords: substance p, neurokinin, tachykinin, nk1 antagonist, depression, emesis, anxiety
Current Topics in Medicinal Chemistry
Title: Medicinal Chemistry of Selective Neurokinin-1 Antagonists
Volume: 3 Issue: 12
Author(s): John M. Humphrey
Affiliation:
Keywords: substance p, neurokinin, tachykinin, nk1 antagonist, depression, emesis, anxiety
Abstract: The study of tachykinin NK1 (substance P) receptor antagonists has emerged as a field of great promise due to accumulating evidence that NK1 antagonists offer possible new treatment options in therapeutic areas ranging from pain, emesis, and pulmonary disorders to depression and anxiety. It is hoped that the unique mechanism of action of these agents, which involves modulation of effects mediated by the interaction of the neuropeptide substance P with its Gprotein coupled receptor, will provide improvements over existing therapies. For this reason many pharmaceutical companies are engaged in intense research programs with the goal of bringing safe and effective new drugs to the market. To date a wealth of diverse NK1 antagonists have been discovered, several of which have been evaluated in clinical trials. Despite rich structural diversity in this area of medicinal chemistry a number of structural features are commonly shared amongst otherwise unrelated antagonists. This theme and others are covered with the aim of conveying recent successful approaches to the discovery of potent and selective nonpeptide NK1 antagonists. This review focuses mainly on reports appearing in the year 2001 and the first half of 2002.
Export Options
About this article
Cite this article as:
Humphrey M. John, Medicinal Chemistry of Selective Neurokinin-1 Antagonists, Current Topics in Medicinal Chemistry 2003; 3 (12) . https://dx.doi.org/10.2174/1568026033451925
DOI https://dx.doi.org/10.2174/1568026033451925 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Post Marketing Surveillance on Safety and Efficacy of IMOD in Iranian Patients with HIV/AIDS
Infectious Disorders - Drug Targets Aging as an Evolvability-Increasing Program Which can be Switched Off by Organism to Mobilize Additional Resources for Survival
Current Aging Science Proanthocyanidins in Health Care: Current and New Trends
Current Medicinal Chemistry The Promise of Slow Down Ageing May Come from Curcumin
Current Pharmaceutical Design Editorial (Thematic Issue: Phytochemicals, Intracellular Signalling Pathways and Anti-Cancer Effects)
Anti-Cancer Agents in Medicinal Chemistry Nicotine and Gastrointestinal Disorders: Its Role in Ulceration and Cancer Development
Current Pharmaceutical Design Evaluation of Vancoplus Versus Ceftriaxone Against Cephalosporin Resistance MRSA Strain in Experimental Meningitis Model
Cardiovascular & Hematological Disorders-Drug Targets Mechanism of Conjugated Imine and Iminium Species, including Marine Alkaloids: Electron Transfer, Reactive Oxygen Species, Therapeutics and Toxicity
Current Bioactive Compounds Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients
Current Hypertension Reviews The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders
Current Drug Targets Subject Index To Volume 7
Current Pharmaceutical Biotechnology Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors
Current Drug Metabolism Foreword
Current Topics in Medicinal Chemistry Doxycycline Inhibition of Abdominal Aortic Aneurysm Growth - A Systematic Review of the Literature
Current Vascular Pharmacology Drug Interactions of Tipranavir, a New HIV Protease Inhibitor
Drug Metabolism Letters Editorial: Pain in Dementia: A Distressing Combination of Several Factors
Current Alzheimer Research Role of Synovial Fibroblasts in Rheumatoid Arthritis
Current Pharmaceutical Design Alzheimer’s Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome
Current Neuropharmacology